Market value added (MVA) is the difference between a firm fair value and its invested capital. MVA is a measure of the value a company has created in excess of the resources already committed to the enterprise.
Paying user area
Try for free
Medtronic PLC pages available for free this week:
- Common-Size Income Statement
- Common-Size Balance Sheet: Assets
- Common-Size Balance Sheet: Liabilities and Stockholders’ Equity
- Common Stock Valuation Ratios
- Capital Asset Pricing Model (CAPM)
- Operating Profit Margin since 2005
- Return on Assets (ROA) since 2005
- Debt to Equity since 2005
- Price to Operating Profit (P/OP) since 2005
- Price to Book Value (P/BV) since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Medtronic PLC for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
MVA
Based on: 10-K (reporting date: 2026-04-24), 10-K (reporting date: 2025-04-25), 10-K (reporting date: 2024-04-26), 10-K (reporting date: 2023-04-28), 10-K (reporting date: 2022-04-29), 10-K (reporting date: 2021-04-30).
1 Fair value of debt. See details »
2 Invested capital. See details »
An analysis of the market value added (MVA) from April 2021 to April 2026 reveals a substantial contraction in the premium the market assigns to the organization over its invested capital. While a positive MVA was maintained throughout the period, the magnitude of this value has decreased significantly, indicating a decline in market capitalization relative to the capital employed in the business.
- Market Value Trends
- A marked decline is observed in the fair market value, which fell from a peak of 190,499 million USD in 2021 to 121,450 million USD by 2026. This trajectory is characterized by a sharp initial drop between 2021 and 2022, followed by a period of volatility, including a temporary recovery in 2025 before declining again in 2026.
- Invested Capital Stability
- The invested capital remained remarkably consistent over the six-year period, fluctuating within a narrow range between a low of 68,670 million USD in 2024 and a high of 72,405 million USD in 2021. This stability indicates that the changes in MVA were not driven by significant expansions or contractions in the capital base.
- Market Value Added (MVA) Dynamics
- The MVA experienced a severe compression, plummeting from 118,094 million USD in 2021 to 50,362 million USD in 2026. The most significant erosion of value occurred between 2021 and 2022, where MVA decreased by approximately 44.7%. Because the invested capital remained nearly flat, the reduction in MVA is directly attributable to the compression of the market's valuation of the entity.
- Correlation and Insights
- There is a direct correlation between the market fair value and the MVA. The brief uptick in MVA observed in 2025 corresponds precisely with the increase in market value, confirming that the MVA is currently driven by external market sentiment rather than internal changes in invested capital. The overall downward trend suggests a diminishing market premium over the book value of the invested capital.
MVA Spread Ratio
| Apr 24, 2026 | Apr 25, 2025 | Apr 26, 2024 | Apr 28, 2023 | Apr 29, 2022 | Apr 30, 2021 | ||
|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||
| Market value added (MVA)1 | |||||||
| Invested capital2 | |||||||
| Performance Ratio | |||||||
| MVA spread ratio3 | |||||||
| Benchmarks | |||||||
| MVA Spread Ratio, Competitors4 | |||||||
| Abbott Laboratories | |||||||
| Elevance Health Inc. | |||||||
| Intuitive Surgical Inc. | |||||||
| UnitedHealth Group Inc. | |||||||
Based on: 10-K (reporting date: 2026-04-24), 10-K (reporting date: 2025-04-25), 10-K (reporting date: 2024-04-26), 10-K (reporting date: 2023-04-28), 10-K (reporting date: 2022-04-29), 10-K (reporting date: 2021-04-30).
1 MVA. See details »
2 Invested capital. See details »
3 2026 Calculation
MVA spread ratio = 100 × MVA ÷ Invested capital
= 100 × ÷ =
4 Click competitor name to see calculations.
The financial performance indicators for Medtronic PLC between April 2021 and April 2026 reveal a significant contraction in market-perceived value creation relative to the capital employed. While the capital base has remained remarkably stable, the market value added has experienced a substantial long-term decline, leading to a compression of the MVA spread ratio.
- Market Value Added (MVA)
- A pronounced downward trajectory is observed in the MVA, which fell from a peak of US$ 118,094 million in April 2021 to US$ 50,362 million by April 2026. The most significant erosion occurred between 2021 and 2022, where value dropped by approximately 44.7%. Despite a temporary recovery in April 2025 to US$ 61,120 million, the value subsequently declined again, indicating volatility in market valuation and a general trend of diminished excess value.
- Invested Capital
- Invested capital has exhibited high stability over the six-year period, fluctuating within a narrow range between US$ 68,670 million and US$ 72,405 million. This consistency indicates that the changes observed in the MVA and the spread ratio are driven by external market valuation factors rather than significant changes in the company's internal capital structure or investment levels.
- MVA Spread Ratio
- The MVA spread ratio exhibits a strong negative correlation with the timeline, declining from 163.10% in April 2021 to 70.84% in April 2026. This decline represents a reduction in the premium the market assigns to the company's invested capital. The ratio remained below 100% from April 2022 onwards, suggesting that the market's valuation of the company's ability to generate value above its cost of capital has weakened considerably compared to the 2021 baseline.
In summary, the data indicates a decoupling between a stable capital investment strategy and a declining market valuation. The persistent drop in the MVA spread ratio underscores a diminishing market confidence in the company's capacity to create significant incremental value over its invested capital base.
MVA Margin
| Apr 24, 2026 | Apr 25, 2025 | Apr 26, 2024 | Apr 28, 2023 | Apr 29, 2022 | Apr 30, 2021 | ||
|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||
| Market value added (MVA)1 | |||||||
| Net sales | |||||||
| Add: Increase (decrease) in deferred revenue | |||||||
| Adjusted net sales | |||||||
| Performance Ratio | |||||||
| MVA margin2 | |||||||
| Benchmarks | |||||||
| MVA Margin, Competitors3 | |||||||
| Abbott Laboratories | |||||||
| Elevance Health Inc. | |||||||
| Intuitive Surgical Inc. | |||||||
| UnitedHealth Group Inc. | |||||||
Based on: 10-K (reporting date: 2026-04-24), 10-K (reporting date: 2025-04-25), 10-K (reporting date: 2024-04-26), 10-K (reporting date: 2023-04-28), 10-K (reporting date: 2022-04-29), 10-K (reporting date: 2021-04-30).
1 MVA. See details »
2 2026 Calculation
MVA margin = 100 × MVA ÷ Adjusted net sales
= 100 × ÷ =
3 Click competitor name to see calculations.
The financial performance from April 2021 to April 2026 reveals a notable divergence between operational growth and market-based value creation.
- Market Value Added (MVA)
- A significant overall decline is observed in the MVA, which dropped from 118,094 million US$ in 2021 to 50,362 million US$ by 2026. The most substantial contraction occurred between 2021 and 2022, where the value fell by nearly 45%. Although a temporary recovery to 61,120 million US$ was recorded in 2025, the value returned to a downward trajectory in 2026.
- Adjusted Net Sales
- Operational expansion is evident through a consistent increase in adjusted net sales. Revenue grew from 30,182 million US$ in 2021 to 36,418 million US$ in 2026. This steady growth indicates a strengthening of the company's top-line performance over the six-year period.
- MVA Margin
- The MVA margin experienced a sharp contraction, falling from 391.27% in 2021 to 138.29% in 2026. This decline demonstrates that the market valuation of the company's value creation has diminished significantly relative to its sales volume. A brief improvement to 182.29% in 2025 was unable to offset the broader trend of margin erosion, suggesting a decrease in the market's premium assigned to the company's growth.